FindTrial
Sign In

A Comparative Study of the Efficacy and Safety of the ACHP-THP Regimen and TCbHP Regimen in Neoadjuvant Therapy for Hormone Receptor-Positive HER2-Positive Breast Cancer

A Comparative Study of the Efficacy and Safety of the ACHP-THP Regimen and TCbHP Regimen in Neoadjuvant Therapy for Hormone Receptor-Positive HER2-Positive Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122648
Enrollment
Unknown
Registered
2026-04-16
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

TCbHP regimen group:None
ACHP-THP regimen group:None

Sponsors

Guangxi Medical University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Female patients aged between 18 and 70 years old; 2. The pathological biopsy result of tumor biopsy shows malignant tumor; 3. Molecular typing HR and HER2 are both positive; 4. NAC treatment has been completed according to the established protocol; 5. No distant metastasis.

Exclusion criteria

Exclusion criteria: 1. Received other neoadjuvant therapies before enrollment; 2. Merge patients with malignant tumors in other parts of the body; 3. Male patients with breast cancer; 4. Inflammatory breast cancer patients.

Design outcomes

Primary

MeasureTime frame
Pathological complete remission rate;—

Secondary

MeasureTime frame
Metastasis, recurrence, and death;—

Countries

China

Contacts

Public ContactHuawei Yang

Guangxi Medical University Cancer Hospital

Lordyhw@163.com+86 771 5308635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026